(RGC) Regencell Bioscience - Overview
Stock: Herbal, Capsule, Syrup, Extract, Powder
| Risk 5d forecast | |
|---|---|
| Volatility | 209% |
| Relative Tail Risk | -35.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.49 |
| Alpha | -3.00 |
| Character TTM | |
|---|---|
| Beta | -0.095 |
| Beta Downside | -1.777 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.15% |
| CAGR/Max DD | 2.53 |
Description: RGC Regencell Bioscience January 11, 2026
Regencell Bioscience Holdings Ltd (NASDAQ:RGC) is a Hong Kong-based biotech firm that applies Traditional Chinese Medicine (TCM) to develop therapies for neurocognitive disorders, with its current pipeline targeting attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Incorporated in 2014 and headquartered in Causeway Bay, the company positions itself within the GICS Biotechnology sub-industry and trades as a common stock.
Key industry context: the global TCM market is projected to exceed US$120 billion by 2027, driven by rising consumer acceptance of integrative health solutions and supportive regulatory frameworks in China and Hong Kong. Regencell’s most advanced candidate, RGC-001, has completed Phase 1 safety trials, and the firm reported a cash runway of roughly US$15 million as of its latest 10-Q, sufficient for at least 12 months of R&D without additional financing. The broader biotech sector’s capital efficiency has been pressured by higher discount rates, making cash-burn visibility a critical valuation driver.
For a deeper, data-rich assessment of RGC’s risk-adjusted upside, you may find the analytical tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA 0.26 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.35 > 3% & CFO -2.00m > Net Income -4.51m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (494.5m) vs 12m ago 0.00% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -1.70 > 6 (EBITDA TTM -4.42m / Interest Expense TTM 1.67m) |
Altman Z'' -15.00
| A: 0.74 (Total Current Assets 4.90m - Total Current Liabilities 663.7k) / Total Assets 5.76m |
| B: -4.38 (Retained Earnings -25.2m / Total Assets 5.76m) |
| C: -0.40 (EBIT TTM -2.84m / Avg Total Assets 7.10m) |
| D: -28.21 (Book Value of Equity -25.3m / Total Liabilities 895.3k) |
| Altman-Z'' Score: -41.76 = D |
What is the price of RGC shares?
Over the past week, the price has changed by +8.96%, over one month by -17.56%, over three months by +105.35% and over the past year by +0.00%.
Is RGC a buy, sell or hold?
What are the forecasts/targets for the RGC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 28.8 | 5.7% |
RGC Fundamental Data Overview February 02, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -2.84m USD
EBITDA TTM = -4.42m USD
Long Term Debt = 231.6k USD (estimated: total debt 544.4k - short term 312.8k)
Short Term Debt = 312.8k USD (from shortTermDebt, last quarter)
Debt = 544.4k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.87m USD (from netDebt column, last quarter)
Enterprise Value = 12.35b USD (12.36b + Debt 544.4k - CCE 4.90m)
Interest Coverage Ratio = -1.70 (Ebit TTM -2.84m / Interest Expense TTM 1.67m)
EV/FCF = -1000.0x (Enterprise Value 12.35b / FCF TTM -2.00m)
FCF Yield = -0.02% (FCF TTM -2.00m / Enterprise Value 12.35b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 392.7k) / Revenue TTM)
Tobins Q-Ratio = 2146 (set to none) (Enterprise Value 12.35b / Total Assets 5.76m)
Interest Expense / Debt = 664.7% (Interest Expense 3.62m / Debt 544.4k)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.25m (EBIT -2.84m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.39 (Total Current Assets 4.90m / Total Current Liabilities 663.7k)
Debt / Equity = 0.11 (Debt 544.4k / totalStockholderEquity, last quarter 4.86m)
Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -1.87m / EBITDA -4.42m)
Debt / FCF = 0.94 (negative FCF - burning cash) (Net Debt -1.87m / FCF TTM -2.00m)
Total Stockholder Equity = 6.63m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.58% (Net Income -4.51m / Total Assets 5.76m)
RoE = -68.08% (Net Income TTM -4.51m / Total Stockholder Equity 6.63m)
RoCE = -41.46% (EBIT -2.84m / Capital Employed (Equity 6.63m + L.T.Debt 231.6k))
RoIC = -27.33% (negative operating profit) (NOPAT -2.25m / Invested Capital 8.22m)
WACC = 5.56% (E(12.36b)/V(12.36b) * Re(5.56%) + (debt cost/tax rate unavailable))
Discount Rate = 5.56% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.00%
Fair Price DCF = unknown (Cash Flow -2.00m)
EPS Correlation: 43.51 | EPS CAGR: 0.09% | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0